[A19-41] Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Last updated 22.11.2019
Project no.:
A19-41
Commission:
Commission awarded on 03.05.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Adults with moderate to severe plaque psoriasis
Proof of considerable added benefit for patients with inadequate response or intolerance to systemic therapy. Due to a lack of relevant study data, an added benefit is not proven for patients who are not candidates for conventional therapy in the framework of a first systemic therapy.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-87 | Risankizumab (plaque psoriasis) - Addendum to Commission A19-41 | Commission completed |
| G19-16 | Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41 | Commission completed |
| A22-133 | Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V | Commission completed |
| A21-156 | Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-11-22 A G-BA decision was published.